These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
67 related articles for article (PubMed ID: 7574756)
1. [Therapeutic effectiveness of hyperthermia and relation to glutathione concentration in the tumor tissues]. Nakagawa S; Yoshikawa T; Boku Y; Arai M; Kondo M; Hirata I; Kokura S Gan To Kagaku Ryoho; 1995 Sep; 22(11):1549-50. PubMed ID: 7574756 [No Abstract] [Full Text] [Related]
2. Depletion of glutathione in normal and malignant human cells in vivo by buthionine sulfoximine: clinical and biochemical results. O'Dwyer PJ; Hamilton TC; Young RC; LaCreta FP; Carp N; Tew KD; Padavic K; Comis RL; Ozols RF J Natl Cancer Inst; 1992 Feb; 84(4):264-7. PubMed ID: 1734088 [No Abstract] [Full Text] [Related]
3. Buthionine sulfoximine pretreatment potentiates the effect of isolated lung perfusion with doxorubicin. Port JL; Hochwald SN; Wang HY; Burt ME Ann Thorac Surg; 1995 Aug; 60(2):239-43; discussion 244. PubMed ID: 7544099 [TBL] [Abstract][Full Text] [Related]
4. Sensitive enzymatic cycling assay for glutathione: measurements of glutathione content and its modulation by buthionine sulfoximine in vivo and in vitro in human colon cancer. Berger SJ; Gosky D; Zborowska E; Willson JK; Berger NA Cancer Res; 1994 Aug; 54(15):4077-83. PubMed ID: 8033140 [TBL] [Abstract][Full Text] [Related]
5. [Use of inhibitors of glutathione and glutathione transferase for overcoming resistance of tumor to cytostatics in an in vivo system]. Donenko FV; Sitdikova SM; Kabieva AO; Polotskiĭ BE; Machaladze ZO; Davydov MI; Moroz LV Biull Eksp Biol Med; 1995 Feb; 119(2):212-4. PubMed ID: 7670058 [No Abstract] [Full Text] [Related]
6. Reduction in cellular glutathione by buthionine sulfoximine and sensitization of murine tumor cells resistant to L-phenylalanine mustard. Somfai-Relle S; Suzukake K; Vistica BP; Vistica DT Biochem Pharmacol; 1984 Feb; 33(3):485-90. PubMed ID: 6704165 [No Abstract] [Full Text] [Related]
7. Variable baseline gamma-glutamylcysteine synthetase messenger RNA expression in peripheral mononuclear cells of cancer patients, and its induction by buthionine sulfoximine treatment. Yao K; Godwin AK; Ozols RF; Hamilton TC; O'Dwyer PJ Cancer Res; 1993 Aug; 53(16):3662-6. PubMed ID: 8101766 [TBL] [Abstract][Full Text] [Related]
8. Depletion of glutathione in normal and malignant human cells in vivo by L-buthionine sulfoximine: possible interaction with ascorbate. Meister A J Natl Cancer Inst; 1992 Oct; 84(20):1601-2. PubMed ID: 1285780 [No Abstract] [Full Text] [Related]
9. Buthionine sulfoximine reduces the protective capacity of myocytes to withstand peroxide-derived free radical attack. Le CT; Hollaar L; van der Valk EJ; van der Laarse A J Mol Cell Cardiol; 1993 May; 25(5):519-28. PubMed ID: 8104252 [TBL] [Abstract][Full Text] [Related]
10. Stereospecific effects of R-lipoic acid on buthionine sulfoximine-induced cataract formation in newborn rats. Maitra I; Serbinova E; Tritschler HJ; Packer L Biochem Biophys Res Commun; 1996 Apr; 221(2):422-9. PubMed ID: 8619871 [TBL] [Abstract][Full Text] [Related]
11. [Rhythmic component of twelve hours]. Metzger G; Li XM; Mormont C; Lévi F Pathol Biol (Paris); 1996 Mar; 44(3):179-82. PubMed ID: 8761605 [TBL] [Abstract][Full Text] [Related]
12. Role of glutathione in cyclosporine A in vitro hepatotoxicity. Wolf A; Trendelenburg CF; Diez-Fernandez C; Prieto P; Cordier A Transplant Proc; 1994 Oct; 26(5):2912-4. PubMed ID: 7940920 [No Abstract] [Full Text] [Related]
13. The glutathione status of rat kidney nuclei following administration of buthionine sulfoximine. Tirmenstein MA; Reed DJ Biochem Biophys Res Commun; 1988 Sep; 155(2):956-61. PubMed ID: 3421975 [TBL] [Abstract][Full Text] [Related]
15. Evidence for embryonic peroxidase-catalyzed bioactivation and glutathione-dependent cytoprotection in phenytoin teratogenicity: modulation by eicosatetraynoic acid and buthionine sulfoximine in murine embryo culture. Miranda AF; Wiley MJ; Wells PG Toxicol Appl Pharmacol; 1994 Feb; 124(2):230-41. PubMed ID: 8122268 [TBL] [Abstract][Full Text] [Related]
16. The role of glutathione in drug resistance. Ozols RF; O'Dwyer PJ; Hamilton TC; Young RC Cancer Treat Rev; 1990 Dec; 17 Suppl A():45-50. PubMed ID: 2092870 [No Abstract] [Full Text] [Related]
17. Glutathione depletion in human T lymphocytes: analysis of activation-associated gene expression and the stress response. Walsh AC; Michaud SG; Malossi JA; Lawrence DA Toxicol Appl Pharmacol; 1995 Aug; 133(2):249-61. PubMed ID: 7645021 [TBL] [Abstract][Full Text] [Related]
18. Combined effects of buthionine sulfoximine and cepharanthine on cytotoxic activity of doxorubicin to multidrug-resistant cells. Kisara S; Furusawa S; Murata R; Ogata M; Hikichi N; Takayanagi Y; Sasaki K Oncol Res; 1995; 7(3-4):191-200. PubMed ID: 8555653 [TBL] [Abstract][Full Text] [Related]
19. Buthionine sulfoximine, an experimental tool to induce glutathione deficiency: elucidation of glutathione and ascorbate in their role as antioxidants. Broquist HP Nutr Rev; 1992 Apr; 50(4 ( Pt 1)):110-1. PubMed ID: 1614638 [TBL] [Abstract][Full Text] [Related]
20. Buthionine sulfoximine spares intracellular glutamate: a possible mechanism for cell growth stimulation. Kang YJ Cell Mol Biol Res; 1993; 39(7):675-84. PubMed ID: 8055000 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]